Concepta PLC Grant of Options (9439G)
July 29 2019 - 2:01AM
UK Regulatory
TIDMCPT
RNS Number : 9439G
Concepta PLC
29 July 2019
29 July 2019
Concepta Plc
("Concepta" or the "Company")
Grant of Options
Concepta plc ("Concepta" or the "Company") (AIM: CPT), the
innovative UK personalised healthcare company and developer of the
proprietary self-test platform ("myLotus(R)") and suite of emerging
test products targeting the mobile health market with a primary
focus on women's fertility and hormone health, announces that the
Company has today granted share options over a total of 1,203,900
ordinary shares of 2.5 pence each in the capital of the Companty
(the "New Share Options"). The New Share Options represent
approximately 0.45% of the issued ordinary share capital and have
been awarded to Chief Operating Officer David Darrock under the EMI
Share Option Scheme at exercise prices of 4p and 3p, respectively,
per share.
The Options shall time vest as follows:
500,000 New Share Options of 4p will vest in 3 tranches :
166,667 on 29(th) January 2020, 166,667 on 29(th) January 2021 and
166,666 on 29(th) January 2022 and 703,900 New Share Options of 3p
will vest equally in three tranches annually over the next 3 years
234,634 on 29th January 2020, 234,633 on 29(th) January 2021 and
234,633 on 29(th) January 2022 .
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
David John Darrock
--------------------------------------- --------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------
a) Position/status Chief Operating Officer
--------------------------------------- --------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------- --------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------
a) Name CONCEPTA PLC
--------------------------------------- --------------------------------------------
b) LEI 213800RBHY6LZDG13168
--------------------------------------- --------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------------------
a) Description of the Options under the Company's EMI Share
financial instrument, Option Scheme
type of instrument
Identification code ISIN: GB00BYZ2R301
b) Nature of the transaction Grant of Options
--------------------------------------- --------------------------------------------
c) Price(s) and volume(s)
-------------------- -------------------
Price(s) Volume(s)
-------------------- -------------------
GBP0.04 500,000
----------------------------------------------------------------- -------------------
GBP0.03 703,900
----------------------------------------------------------------- -------------------
d) Aggregated information
- Aggregated volume 1,203,900
- Price GBP0.03 and GBP0.04 as above
e) Date of the transaction 29 July 2019
--------------------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------------------- --------------------------------------------
Enquiries:
The Company www.conceptaplc.com, Product: www.mylotus.com
Matthew Walls
Executive Chairman
Tel +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin
Tel: +44 (0)20 368 3550
Novum Securities (Broker)
Colin Rowbury
+44 (0) 20 7399 9400
Concepta Plc:
Concepta Plc is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalised mobile health market with a primary focus on
hormone testing and increasing a woman's chances of naturally
getting pregnant and to provide insight to unexplained.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2019.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEAAXPAEXNEFF
(END) Dow Jones Newswires
July 29, 2019 02:01 ET (06:01 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2023 to Apr 2024
